Payment overview · 2025
General Payments
$334.13
10 reported records · 3 companies
Healthcare provider profile · identity verified
Eileen Diaz Cabrera
Allopathic & Osteopathic Physicians|General Practice · JUNCOS, PR · NPI 1902801822
Verified facts
What the public records show
CMS Open Payments records show Eileen Diaz Cabrera received $334.13 in general payments during 2025 across 10 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $165.42 | 49.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.71 | 35.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.00 | 15.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $334.13 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $165.42 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $118.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Synthroid | Levothyroxine Sodium | 594 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 580 | 126 |
| Omeprazole | Omeprazole | 392 | 72 |
| Famotidine | Famotidine | 366 | 67 |
| Gabapentin | Gabapentin | 350 | 67 |
| Metformin Hcl | Metformin Hcl | 332 | 63 |
| Losartan Potassium | Losartan Potassium | 301 | 65 |
| Alendronate Sodium | Alendronate Sodium | 284 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 39 |
| Montelukast Sodium | Montelukast Sodium | 195 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 32 |
| Lisinopril | Lisinopril | 166 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 112 | 19 |
| Meloxicam | Meloxicam | 110 | 46 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 104 | 22 |
| Candesartan Cilexetil | Candesartan Cilexetil | 101 | 20 |
| Enalapril Maleate | Enalapril Maleate | 101 | 19 |
| Simvastatin | Simvastatin | 98 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 21 |
| Diclofenac Potassium | Diclofenac Potassium | 87 | 31 |
| Farxiga | Dapagliflozin Propanediol | 87 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 15 |
| Jardiance | Empagliflozin | 84 | 17 |
| Sertraline Hcl | Sertraline Hcl | 81 | 19 |
| Irbesartan | Irbesartan | 74 | 16 |
| Januvia | Sitagliptin Phosphate | 74 | 12 |
| Memantine Hcl | Memantine Hcl | 72 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 17 |
| Eliquis | Apixaban | 50 | suppressed |
| Alprazolam | Alprazolam | 49 | suppressed |
| Carvedilol | Carvedilol | 49 | 11 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Finasteride | Finasteride | 48 | 11 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | suppressed |
| Furosemide | Furosemide | 42 | 13 |
| Nitroglycerin | Nitroglycerin | 42 | 11 |
| Clonazepam | Clonazepam | 41 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Pentoxifylline | Pentoxifylline | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 22 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Galantamine Er | Galantamine Hbr | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Prednisone | Prednisone | 17 | 13 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Techlite Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $334.13 · 10 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, JARDIANCE, LOKELMA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error